One year after approval, the first mitochondria-targeted drug reports $17.5 million in early sales

Elamipretide has been in development for well over a decade under a string of names and owners. This week its current maker, Mighty Therapeutics, marked the first anniversary of FORZINITY's FDA approval — September 19, 2025, under accelerated approval, to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg — with the first detailed look at how the launch is actually going.

Barth syndrome is a rare, life-threatening mitochondrial disease. FORZINITY is a mitochondrial cardiolipin binder: it targets cardiolipin, the signature lipid of the inner mitochondrial membrane, aiming to stabilize the membrane structures where energy production happens.

What do the first-year numbers show?

All of the following figures are company-reported and unaudited. From the December 2025 soft launch through September 2026, Mighty reports $17.5 million in gross revenue, including $8.1 million in the third quarter of 2026 alone; 60 patient enrollment forms received; 48 unique prescribers; and reimbursement access covering more than 90% of lives across major national US health plans. The company also said it has secured up to $150 million in non-dilutive growth and equity capital, which it expects to fund operations to projected cash-flow positivity in early 2029.

What still has to be proven?

Accelerated approval is a promissory note: FORZINITY was approved on an intermediate endpoint — improved knee-extensor muscle strength — and continued approval depends on confirmatory evidence. The global Phase 4 4TAZPower study, designed to confirm efficacy, safety, and pharmacokinetics of once-daily elamipretide in patients aged five and up, has now dosed its first participant, with sites initiated in Canada, Australia, Ireland, and the UK. A long-term patient registry launching by year-end is also intended to support full approval. Separately, the company is preparing a pediatric dosing study aimed at a 2027 application to extend treatment to children weighing as little as 7 kg, and continues treating the smallest children through expanded access.

Where else is elamipretide being tested?

The pipeline update spans the mitochondrial map: a fully enrolled Phase 3 trial in dry age-related macular degeneration (ReNEW) remains on track for top-line data in the second half of 2027; a pivotal trial in POLG-related mitochondrial disease is being planned with the FDA for a 2027 start; and preclinical work continues in Parkinson's disease, Leigh syndrome, and Friedreich's ataxia, plus an XPRIZE Healthspan-recognized plan for a placebo-controlled trial of elamipretide in healthy older adults running through 2029. Each of those is a separate evidentiary mountain — none should be read as an approved use.

Where the evidence stands

• Established: FORZINITY (elamipretide) received FDA accelerated approval on September 19, 2025 to improve muscle strength in Barth syndrome patients weighing at least 30 kg, based on an intermediate endpoint (knee-extensor strength); continued approval is contingent on confirmatory trials.
• Preliminary: Company-reported launch figures (Oct 14, 2026): $17.5M gross revenue since December 2025 soft launch, 60 enrollment forms, 48 prescribers, >90% payer coverage; confirmatory Phase 4 4TAZPower study underway internationally.
• Absent: Confirmatory evidence of clinical benefit required for full approval, and any approved use of elamipretide beyond Barth syndrome (dry AMD, POLG, Parkinson's, and aging uses remain investigational).